Press coverage about Bruker (NASDAQ:BRKR) has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bruker earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.7088869735254 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

BRKR has been the topic of several recent research reports. Zacks Investment Research upgraded Bruker from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research report on Wednesday, November 8th. Morgan Stanley restated an “equal weight” rating and set a $35.00 target price on shares of Bruker in a report on Thursday, December 14th. Cowen restated a “hold” rating and set a $35.00 target price on shares of Bruker in a report on Thursday, December 21st. Citigroup increased their target price on Bruker from $29.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Finally, Bank of America upgraded Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price for the company in a report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $30.58.

Bruker (NASDAQ:BRKR) traded up $0.03 during midday trading on Tuesday, reaching $34.11. The company’s stock had a trading volume of 282,046 shares, compared to its average volume of 622,879. Bruker has a 1-year low of $21.10 and a 1-year high of $36.53. The company has a current ratio of 2.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.65. The stock has a market cap of $5,301.58, a PE ratio of 36.29, a P/E/G ratio of 2.88 and a beta of 1.12.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.02. Bruker had a return on equity of 25.83% and a net margin of 8.85%. The business had revenue of $435.60 million during the quarter, compared to analysts’ expectations of $415.45 million. During the same quarter last year, the business posted $0.32 EPS. The business’s revenue was up 10.6% on a year-over-year basis. equities analysts forecast that Bruker will post 1.19 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 22nd. Shareholders of record on Monday, December 4th were issued a $0.04 dividend. This represents a $0.16 annualized dividend and a yield of 0.47%. The ex-dividend date was Friday, December 1st. Bruker’s dividend payout ratio (DPR) is currently 17.02%.

COPYRIGHT VIOLATION NOTICE: This article was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at

About Bruker

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Insider Buying and Selling by Quarter for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with Analyst Ratings Network's FREE daily email newsletter.